Tocilizumab

Generic Name
Tocilizumab
Brand Names
Actemra, RoActemra, Tyenne, Tofidence
Drug Type
Biotech
Chemical Formula
-
CAS Number
375823-41-9
Unique Ingredient Identifier
I031V2H011
Background

Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication

Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions
Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
Monotherapy
Clinical Trials
Related News

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

First Posted Date
2020-05-19
Last Posted Date
2022-03-29
Lead Sponsor
Fundacion GenesisCare
Target Recruit Count
15
Registration Number
NCT04394182
Locations
🇪🇸

Hospital La Milagrosa, GenesisCare, Madrid, Spain

🇪🇸

Hospital Vithas Valencia Consuelo, Valencia, Spain

Randomised Evaluation of COVID-19 Therapy

First Posted Date
2020-05-11
Last Posted Date
2024-01-05
Lead Sponsor
University of Oxford
Target Recruit Count
70000
Registration Number
NCT04381936
Locations
🇻🇳

Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam

🇬🇭

Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana

🇮🇳

Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India

and more 4 locations

The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

Phase 4
Conditions
Covid19 Pneumonia
Interventions
Drug: Tocilizumab
First Posted Date
2020-05-06
Last Posted Date
2020-05-06
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
500
Registration Number
NCT04377750
Locations
🇮🇱

Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel

🇮🇱

Barzilai Medical Center, Ashkelon, Israel

🇮🇱

Wolfson Medical Center, H̱olon, Israel

and more 1 locations

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Phase 2
Terminated
Conditions
COVID-19
Interventions
Drug: Tocilizumab
First Posted Date
2020-05-06
Last Posted Date
2023-06-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
9
Registration Number
NCT04377659
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Rituximab or Tocilizumab for Patients with Steroid-Dependent Immune-Related Adverse Events (irAEs)

First Posted Date
2020-05-05
Last Posted Date
2024-12-16
Lead Sponsor
Columbia University
Target Recruit Count
30
Registration Number
NCT04375228
Locations
🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, United States

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

Phase 3
Completed
Conditions
COVID-19 Pneumonia
Interventions
Drug: Placebo
Drug: Tocilizumab
First Posted Date
2020-05-01
Last Posted Date
2023-02-10
Lead Sponsor
Genentech, Inc.
Target Recruit Count
377
Registration Number
NCT04372186
Locations
🇺🇸

eStudySite, La Mesa, California, United States

🇺🇸

El Centro Regional Medical Center, El Centro, California, United States

🇺🇸

Highland Hospital Oakland, Oakland, California, United States

and more 41 locations

Efficacy of Tocilizumab on Patients With COVID-19

Phase 3
Completed
Conditions
SARS-CoV 2
Interventions
Drug: Placebos
Drug: Tocilizumab
First Posted Date
2020-04-22
Last Posted Date
2021-07-27
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
243
Registration Number
NCT04356937
Locations
🇺🇸

Newton-Wellesley Hospital, Newton, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

First Posted Date
2020-04-16
Last Posted Date
2020-11-12
Lead Sponsor
The Camelot Foundation
Target Recruit Count
1800
Registration Number
NCT04349410
Locations
🇺🇸

FHHI-OI-Camelot; QME, Los Angeles, California, United States

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

Phase 2
Terminated
Conditions
COVID-19 Pneumonia
Interventions
Drug: Tocilizumab
First Posted Date
2020-04-15
Last Posted Date
2020-06-22
Lead Sponsor
Azienda Unità Sanitaria Locale Reggio Emilia
Target Recruit Count
126
Registration Number
NCT04346355
Locations
🇮🇹

Ospedale di Guastalla, Guastalla, RE, Italy

🇮🇹

Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy

🇮🇹

ASST Cremona, Cremona, Italy

and more 22 locations

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression

First Posted Date
2020-04-14
Last Posted Date
2020-04-14
Lead Sponsor
University of Malaya
Target Recruit Count
310
Registration Number
NCT04345445
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy